Innocrin Pharmaceuticals Initiates Phase 2 Study of Seviteronel in Women with Difficult-to-Treat Breast Cancer
News
Innocrin Pharmaceuticals has initiated dosing in a Phase 2 clinical trial in patients with estrogen receptor-positive (ER+) or triple negative breast cancer (TN BCa) to determine the safety, tolerability, pharmacokinetics and activity ... Read more